Review



pathscan total stat3 sandwich elisa kit  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Cell Signaling Technology Inc pathscan total stat3 sandwich elisa kit
    Development of A5, a novel PAI-1–neutralizing antibody. A, Graphical illustration of phage screen and identification of PAI-1–neutralizing antibody. B, Recognition of different conformations of recombinant PAI-1 by A5 in Western blotting. C, A5 neutralized PAI-1 function in inhibiting tPA and uPA. D, Competitive binding of A5 with fluorine-containing tiplaxtinin on stable active PAI-1 assessed by 19F-NMR. E, Inhibition of proliferation of PM cells treated with PAI-1–positive ascites in vitro by 150 µg/mL A5 in biological triplicates. Human IgG served as a negative control. F, <t>STAT3</t> signaling activation upon the exposure to PM ascites was suppressed by A5 as compared with IgG control. G, GSEA comparisons of HALLMARK pathway changes between CRC cells treated with A5 ( n = 2) vs. IgG ( n = 2). Pathways with an FDR adjusted P value of less than 0.05 are opacified. CRC, colorectal cancer; NES, normalized enrichment score.
    Pathscan Total Stat3 Sandwich Elisa Kit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathscan total stat3 sandwich elisa kit/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    pathscan total stat3 sandwich elisa kit - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis"

    Article Title: Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis

    Journal: Clinical Cancer Research

    doi: 10.1158/1078-0432.CCR-24-3780

    Development of A5, a novel PAI-1–neutralizing antibody. A, Graphical illustration of phage screen and identification of PAI-1–neutralizing antibody. B, Recognition of different conformations of recombinant PAI-1 by A5 in Western blotting. C, A5 neutralized PAI-1 function in inhibiting tPA and uPA. D, Competitive binding of A5 with fluorine-containing tiplaxtinin on stable active PAI-1 assessed by 19F-NMR. E, Inhibition of proliferation of PM cells treated with PAI-1–positive ascites in vitro by 150 µg/mL A5 in biological triplicates. Human IgG served as a negative control. F, STAT3 signaling activation upon the exposure to PM ascites was suppressed by A5 as compared with IgG control. G, GSEA comparisons of HALLMARK pathway changes between CRC cells treated with A5 ( n = 2) vs. IgG ( n = 2). Pathways with an FDR adjusted P value of less than 0.05 are opacified. CRC, colorectal cancer; NES, normalized enrichment score.
    Figure Legend Snippet: Development of A5, a novel PAI-1–neutralizing antibody. A, Graphical illustration of phage screen and identification of PAI-1–neutralizing antibody. B, Recognition of different conformations of recombinant PAI-1 by A5 in Western blotting. C, A5 neutralized PAI-1 function in inhibiting tPA and uPA. D, Competitive binding of A5 with fluorine-containing tiplaxtinin on stable active PAI-1 assessed by 19F-NMR. E, Inhibition of proliferation of PM cells treated with PAI-1–positive ascites in vitro by 150 µg/mL A5 in biological triplicates. Human IgG served as a negative control. F, STAT3 signaling activation upon the exposure to PM ascites was suppressed by A5 as compared with IgG control. G, GSEA comparisons of HALLMARK pathway changes between CRC cells treated with A5 ( n = 2) vs. IgG ( n = 2). Pathways with an FDR adjusted P value of less than 0.05 are opacified. CRC, colorectal cancer; NES, normalized enrichment score.

    Techniques Used: Recombinant, Western Blot, Binding Assay, Inhibition, In Vitro, Negative Control, Activation Assay, Control



    Similar Products

    90
    Cell Signaling Technology Inc pathscan total stat3 sandwich elisa kit
    Development of A5, a novel PAI-1–neutralizing antibody. A, Graphical illustration of phage screen and identification of PAI-1–neutralizing antibody. B, Recognition of different conformations of recombinant PAI-1 by A5 in Western blotting. C, A5 neutralized PAI-1 function in inhibiting tPA and uPA. D, Competitive binding of A5 with fluorine-containing tiplaxtinin on stable active PAI-1 assessed by 19F-NMR. E, Inhibition of proliferation of PM cells treated with PAI-1–positive ascites in vitro by 150 µg/mL A5 in biological triplicates. Human IgG served as a negative control. F, <t>STAT3</t> signaling activation upon the exposure to PM ascites was suppressed by A5 as compared with IgG control. G, GSEA comparisons of HALLMARK pathway changes between CRC cells treated with A5 ( n = 2) vs. IgG ( n = 2). Pathways with an FDR adjusted P value of less than 0.05 are opacified. CRC, colorectal cancer; NES, normalized enrichment score.
    Pathscan Total Stat3 Sandwich Elisa Kit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathscan total stat3 sandwich elisa kit/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    pathscan total stat3 sandwich elisa kit - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc pathscan phospho stat3 sandwich elisa kit
    Development of A5, a novel PAI-1–neutralizing antibody. A, Graphical illustration of phage screen and identification of PAI-1–neutralizing antibody. B, Recognition of different conformations of recombinant PAI-1 by A5 in Western blotting. C, A5 neutralized PAI-1 function in inhibiting tPA and uPA. D, Competitive binding of A5 with fluorine-containing tiplaxtinin on stable active PAI-1 assessed by 19F-NMR. E, Inhibition of proliferation of PM cells treated with PAI-1–positive ascites in vitro by 150 µg/mL A5 in biological triplicates. Human IgG served as a negative control. F, <t>STAT3</t> signaling activation upon the exposure to PM ascites was suppressed by A5 as compared with IgG control. G, GSEA comparisons of HALLMARK pathway changes between CRC cells treated with A5 ( n = 2) vs. IgG ( n = 2). Pathways with an FDR adjusted P value of less than 0.05 are opacified. CRC, colorectal cancer; NES, normalized enrichment score.
    Pathscan Phospho Stat3 Sandwich Elisa Kit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathscan phospho stat3 sandwich elisa kit/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    pathscan phospho stat3 sandwich elisa kit - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc sc 7305 rrid ab 626671 aurora kinase a aurka cell signaling technology cat
    Development of A5, a novel PAI-1–neutralizing antibody. A, Graphical illustration of phage screen and identification of PAI-1–neutralizing antibody. B, Recognition of different conformations of recombinant PAI-1 by A5 in Western blotting. C, A5 neutralized PAI-1 function in inhibiting tPA and uPA. D, Competitive binding of A5 with fluorine-containing tiplaxtinin on stable active PAI-1 assessed by 19F-NMR. E, Inhibition of proliferation of PM cells treated with PAI-1–positive ascites in vitro by 150 µg/mL A5 in biological triplicates. Human IgG served as a negative control. F, <t>STAT3</t> signaling activation upon the exposure to PM ascites was suppressed by A5 as compared with IgG control. G, GSEA comparisons of HALLMARK pathway changes between CRC cells treated with A5 ( n = 2) vs. IgG ( n = 2). Pathways with an FDR adjusted P value of less than 0.05 are opacified. CRC, colorectal cancer; NES, normalized enrichment score.
    Sc 7305 Rrid Ab 626671 Aurora Kinase A Aurka Cell Signaling Technology Cat, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sc 7305 rrid ab 626671 aurora kinase a aurka cell signaling technology cat/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    sc 7305 rrid ab 626671 aurora kinase a aurka cell signaling technology cat - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc pathscan phospho stat3 7300
    Development of A5, a novel PAI-1–neutralizing antibody. A, Graphical illustration of phage screen and identification of PAI-1–neutralizing antibody. B, Recognition of different conformations of recombinant PAI-1 by A5 in Western blotting. C, A5 neutralized PAI-1 function in inhibiting tPA and uPA. D, Competitive binding of A5 with fluorine-containing tiplaxtinin on stable active PAI-1 assessed by 19F-NMR. E, Inhibition of proliferation of PM cells treated with PAI-1–positive ascites in vitro by 150 µg/mL A5 in biological triplicates. Human IgG served as a negative control. F, <t>STAT3</t> signaling activation upon the exposure to PM ascites was suppressed by A5 as compared with IgG control. G, GSEA comparisons of HALLMARK pathway changes between CRC cells treated with A5 ( n = 2) vs. IgG ( n = 2). Pathways with an FDR adjusted P value of less than 0.05 are opacified. CRC, colorectal cancer; NES, normalized enrichment score.
    Pathscan Phospho Stat3 7300, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathscan phospho stat3 7300/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    pathscan phospho stat3 7300 - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc stat3 7305 cell signaling technology danvers ma
    Development of A5, a novel PAI-1–neutralizing antibody. A, Graphical illustration of phage screen and identification of PAI-1–neutralizing antibody. B, Recognition of different conformations of recombinant PAI-1 by A5 in Western blotting. C, A5 neutralized PAI-1 function in inhibiting tPA and uPA. D, Competitive binding of A5 with fluorine-containing tiplaxtinin on stable active PAI-1 assessed by 19F-NMR. E, Inhibition of proliferation of PM cells treated with PAI-1–positive ascites in vitro by 150 µg/mL A5 in biological triplicates. Human IgG served as a negative control. F, <t>STAT3</t> signaling activation upon the exposure to PM ascites was suppressed by A5 as compared with IgG control. G, GSEA comparisons of HALLMARK pathway changes between CRC cells treated with A5 ( n = 2) vs. IgG ( n = 2). Pathways with an FDR adjusted P value of less than 0.05 are opacified. CRC, colorectal cancer; NES, normalized enrichment score.
    Stat3 7305 Cell Signaling Technology Danvers Ma, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stat3 7305 cell signaling technology danvers ma/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    stat3 7305 cell signaling technology danvers ma - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc anti p stat3
    Development of A5, a novel PAI-1–neutralizing antibody. A, Graphical illustration of phage screen and identification of PAI-1–neutralizing antibody. B, Recognition of different conformations of recombinant PAI-1 by A5 in Western blotting. C, A5 neutralized PAI-1 function in inhibiting tPA and uPA. D, Competitive binding of A5 with fluorine-containing tiplaxtinin on stable active PAI-1 assessed by 19F-NMR. E, Inhibition of proliferation of PM cells treated with PAI-1–positive ascites in vitro by 150 µg/mL A5 in biological triplicates. Human IgG served as a negative control. F, <t>STAT3</t> signaling activation upon the exposure to PM ascites was suppressed by A5 as compared with IgG control. G, GSEA comparisons of HALLMARK pathway changes between CRC cells treated with A5 ( n = 2) vs. IgG ( n = 2). Pathways with an FDR adjusted P value of less than 0.05 are opacified. CRC, colorectal cancer; NES, normalized enrichment score.
    Anti P Stat3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti p stat3/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    anti p stat3 - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc antibody stat3
    (a): Western blot was used to detect the protein expression of KYSE30 cells treated with different concentrations of compounds. (b): Western blot results showed that the expression of <t>Stat3</t> protein was significantly decreased after treatment with different concentrations of the compounds. (c): The expression of Smad2/3 protein was significantly decreased after treatment with different concentrations of drugs. (d): The expression of cleaved caspase3 protein was significantly increased after treatment with different drug concentrations. Data are shown as the mean±SD and were analyzed with one‐way ANOVA. (*P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001, compared with the control group).
    Antibody Stat3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody stat3/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    antibody stat3 - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc pathscan phospho stat3 y705 sandwich elisa kit
    (a): Western blot was used to detect the protein expression of KYSE30 cells treated with different concentrations of compounds. (b): Western blot results showed that the expression of <t>Stat3</t> protein was significantly decreased after treatment with different concentrations of the compounds. (c): The expression of Smad2/3 protein was significantly decreased after treatment with different concentrations of drugs. (d): The expression of cleaved caspase3 protein was significantly increased after treatment with different drug concentrations. Data are shown as the mean±SD and were analyzed with one‐way ANOVA. (*P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001, compared with the control group).
    Pathscan Phospho Stat3 Y705 Sandwich Elisa Kit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pathscan phospho stat3 y705 sandwich elisa kit/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    pathscan phospho stat3 y705 sandwich elisa kit - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    Image Search Results


    Development of A5, a novel PAI-1–neutralizing antibody. A, Graphical illustration of phage screen and identification of PAI-1–neutralizing antibody. B, Recognition of different conformations of recombinant PAI-1 by A5 in Western blotting. C, A5 neutralized PAI-1 function in inhibiting tPA and uPA. D, Competitive binding of A5 with fluorine-containing tiplaxtinin on stable active PAI-1 assessed by 19F-NMR. E, Inhibition of proliferation of PM cells treated with PAI-1–positive ascites in vitro by 150 µg/mL A5 in biological triplicates. Human IgG served as a negative control. F, STAT3 signaling activation upon the exposure to PM ascites was suppressed by A5 as compared with IgG control. G, GSEA comparisons of HALLMARK pathway changes between CRC cells treated with A5 ( n = 2) vs. IgG ( n = 2). Pathways with an FDR adjusted P value of less than 0.05 are opacified. CRC, colorectal cancer; NES, normalized enrichment score.

    Journal: Clinical Cancer Research

    Article Title: Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis

    doi: 10.1158/1078-0432.CCR-24-3780

    Figure Lengend Snippet: Development of A5, a novel PAI-1–neutralizing antibody. A, Graphical illustration of phage screen and identification of PAI-1–neutralizing antibody. B, Recognition of different conformations of recombinant PAI-1 by A5 in Western blotting. C, A5 neutralized PAI-1 function in inhibiting tPA and uPA. D, Competitive binding of A5 with fluorine-containing tiplaxtinin on stable active PAI-1 assessed by 19F-NMR. E, Inhibition of proliferation of PM cells treated with PAI-1–positive ascites in vitro by 150 µg/mL A5 in biological triplicates. Human IgG served as a negative control. F, STAT3 signaling activation upon the exposure to PM ascites was suppressed by A5 as compared with IgG control. G, GSEA comparisons of HALLMARK pathway changes between CRC cells treated with A5 ( n = 2) vs. IgG ( n = 2). Pathways with an FDR adjusted P value of less than 0.05 are opacified. CRC, colorectal cancer; NES, normalized enrichment score.

    Article Snippet: Then 25 μg of the protein lysate was used to measure total STAT3 and p-STAT3 (Tyr705) by ELISA using the PathScan Total Stat3 Sandwich ELISA kit (Cell Signaling Technology, 7305C) and the PathScan Phospho-Stat3 (Tyr705) Sandwich ELISA kit (Cell Signaling Technology, 7300C), respectively.

    Techniques: Recombinant, Western Blot, Binding Assay, Inhibition, In Vitro, Negative Control, Activation Assay, Control

    (a): Western blot was used to detect the protein expression of KYSE30 cells treated with different concentrations of compounds. (b): Western blot results showed that the expression of Stat3 protein was significantly decreased after treatment with different concentrations of the compounds. (c): The expression of Smad2/3 protein was significantly decreased after treatment with different concentrations of drugs. (d): The expression of cleaved caspase3 protein was significantly increased after treatment with different drug concentrations. Data are shown as the mean±SD and were analyzed with one‐way ANOVA. (*P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001, compared with the control group).

    Journal: ChemistryOpen

    Article Title: Synthesis of compounds based on the active domain of cabotegravir and their application in inhibiting tumor cells activity

    doi: 10.1002/open.202300284

    Figure Lengend Snippet: (a): Western blot was used to detect the protein expression of KYSE30 cells treated with different concentrations of compounds. (b): Western blot results showed that the expression of Stat3 protein was significantly decreased after treatment with different concentrations of the compounds. (c): The expression of Smad2/3 protein was significantly decreased after treatment with different concentrations of drugs. (d): The expression of cleaved caspase3 protein was significantly increased after treatment with different drug concentrations. Data are shown as the mean±SD and were analyzed with one‐way ANOVA. (*P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001, compared with the control group).

    Article Snippet: After washing with TBST solution, the membrane was incubated overnight at 4 °C with the primary antibody Stat3 (1 : 2000, CST), Smad2/3 (1 : 1000, CST), GAPDH (1 : 5000, Sangon Biotech), and cleaved caspase 3 (1 : 1000, CST).

    Techniques: Western Blot, Expressing, Control